TNFRSF11B and ameloblastoma: Based on the fact that Qian et al. (26) found that OPG suppresses both, osteoclastogenesis induced by ameloblastoma and bone resorption caused by osteoclasts, De Matos et al. (27) have suggested that OPG could be used as therapeutic treatment of ameloblastoma in the future to stop bone loss and thus, minimize the extent of bone destruction before surgical management (23).